BRPI1008023A2 - forma de dosagem sólida - Google Patents

forma de dosagem sólida

Info

Publication number
BRPI1008023A2
BRPI1008023A2 BRPI1008023A BRPI1008023A BRPI1008023A2 BR PI1008023 A2 BRPI1008023 A2 BR PI1008023A2 BR PI1008023 A BRPI1008023 A BR PI1008023A BR PI1008023 A BRPI1008023 A BR PI1008023A BR PI1008023 A2 BRPI1008023 A2 BR PI1008023A2
Authority
BR
Brazil
Prior art keywords
dosage form
solid dosage
solid
dosage
Prior art date
Application number
BRPI1008023A
Other languages
English (en)
Inventor
Colin J Meyer
Jiang Zhang
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42335073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1008023(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of BRPI1008023A2 publication Critical patent/BRPI1008023A2/pt
Publication of BRPI1008023B1 publication Critical patent/BRPI1008023B1/pt
Publication of BRPI1008023B8 publication Critical patent/BRPI1008023B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1008023A 2009-02-13 2010-02-12 Forma de dosagem sólida BRPI1008023B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15260809P 2009-02-13 2009-02-13
PCT/US2010/024127 WO2010093944A2 (en) 2009-02-13 2010-02-12 Delayed release, oral dosage compositions that contain amorphous cddo-me

Publications (3)

Publication Number Publication Date
BRPI1008023A2 true BRPI1008023A2 (pt) 2016-03-15
BRPI1008023B1 BRPI1008023B1 (pt) 2019-12-31
BRPI1008023B8 BRPI1008023B8 (pt) 2023-04-11

Family

ID=42335073

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008023A BRPI1008023B8 (pt) 2009-02-13 2010-02-12 Forma de dosagem sólida

Country Status (30)

Country Link
US (2) US8747901B2 (pt)
EP (2) EP2395979B1 (pt)
JP (1) JP5775464B2 (pt)
KR (2) KR20140016441A (pt)
CN (2) CN102387789A (pt)
AU (1) AU2010213594B2 (pt)
BR (1) BRPI1008023B8 (pt)
CA (1) CA2752048C (pt)
CO (1) CO6361904A2 (pt)
CY (2) CY1119595T1 (pt)
DK (2) DK2395979T3 (pt)
EA (1) EA023652B1 (pt)
ES (2) ES2731601T3 (pt)
HK (1) HK1220130A1 (pt)
HR (2) HRP20171639T1 (pt)
HU (2) HUE044005T2 (pt)
IL (1) IL214258A (pt)
LT (2) LT3254675T (pt)
MX (1) MX2011008344A (pt)
MY (1) MY173715A (pt)
NO (1) NO2395979T3 (pt)
NZ (1) NZ594488A (pt)
PL (2) PL2395979T3 (pt)
PT (2) PT2395979T (pt)
SG (1) SG173601A1 (pt)
SI (2) SI2395979T1 (pt)
SM (2) SMT201700527T1 (pt)
TR (1) TR201909743T4 (pt)
WO (1) WO2010093944A2 (pt)
ZA (1) ZA201105630B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
TWI492745B (zh) 2008-01-11 2015-07-21 Reata Pharmaceuticals Inc 合成的三萜系化合物及其使用於治療疾病之方法
WO2009129548A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
MX2010011435A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
EA022588B1 (ru) 2008-04-18 2016-01-29 Ритэ Фамэсутикл, Инк. Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце
DK2276493T3 (da) 2008-04-18 2019-01-02 Reata Pharmaceuticals Inc Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17
AU2009274037B2 (en) 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
ES2731601T3 (es) 2009-02-13 2019-11-18 Reata Pharmaceuticals Inc Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo
ME03713B (me) 2010-04-12 2021-01-20 Reata Pharmaceuticals Inc Bardoksolon meтil za lečenje gojaznosтi
NZ612788A (en) 2010-12-17 2015-10-30 Reata Pharmaceuticals Inc Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
EP2683731B1 (en) 2011-03-11 2019-04-24 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
CN103156861B (zh) * 2011-12-08 2015-11-25 陈丽梅 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
SI3444261T1 (sl) 2012-04-27 2021-04-30 Reata Pharmaceuticals, Inc. 2,2-difluoropropionamidni derivat bardoksolon metila, njegovi farmacevtski sestavki in polimorfi za uporabo pri zdravljenju določenih stanj
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
PL2892912T3 (pl) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
UY35534A (es) 2013-04-24 2014-10-31 Abbvie Inc Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
PH12016500358B1 (en) 2013-08-23 2023-08-16 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
WO2016070063A1 (en) 2014-10-31 2016-05-06 The Regents Of The University Of California Compositions and methods for treating hiv-associated cognitive dysfunction
NZ734292A (en) 2015-02-12 2022-09-30 Reata Pharmaceuticals Inc Imidazolyl tricyclic enones as antioxidant inflammation modulators
MX386256B (es) 2015-09-23 2025-03-18 Reata Pharmaceuticals Inc Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2019005401A (es) 2016-11-08 2019-08-05 Reata Pharmaceuticals Inc Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
US11427533B2 (en) 2017-07-13 2022-08-30 Pliva Hrvatska D.O.O. Crystalline polymorphs of bardoxolone methyl
EP3773509B1 (en) 2018-04-06 2023-11-01 Capsugel Belgium NV Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
IL279348B2 (en) 2018-06-15 2026-01-01 Reata Pharmaceuticals Inc Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
KR20210096162A (ko) 2018-11-27 2021-08-04 쿄와 기린 가부시키가이샤 의약 조성물
WO2021016191A1 (en) 2019-07-19 2021-01-28 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
CN115803059A (zh) 2020-05-09 2023-03-14 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗covid-19的方法
EP4259155A1 (en) 2020-12-11 2023-10-18 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
CN114558019A (zh) * 2022-03-26 2022-05-31 中国科学院昆明动物研究所 一种Rab13基因抑制剂及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
JP2008110962A (ja) 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Nrf2活性化物質を有効成分として含む角結膜障害の予防または治療剤
JP4315182B2 (ja) * 2006-10-30 2009-08-19 ミツミ電機株式会社 カメラモジュール
WO2008111497A1 (ja) * 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
TWI492745B (zh) 2008-01-11 2015-07-21 Reata Pharmaceuticals Inc 合成的三萜系化合物及其使用於治療疾病之方法
ES2731601T3 (es) 2009-02-13 2019-11-18 Reata Pharmaceuticals Inc Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo

Also Published As

Publication number Publication date
SI3254675T1 (sl) 2019-08-30
CY1122066T1 (el) 2020-11-25
KR101483203B1 (ko) 2015-01-15
HUE044005T2 (hu) 2019-09-30
IL214258A (en) 2017-06-29
CN105232471A (zh) 2016-01-13
BRPI1008023B8 (pt) 2023-04-11
NO2395979T3 (pt) 2018-01-20
EP3254675B1 (en) 2019-05-15
HRP20171639T1 (hr) 2017-12-15
WO2010093944A2 (en) 2010-08-19
TR201909743T4 (tr) 2019-07-22
SI2395979T1 (sl) 2017-12-29
SMT201700527T1 (it) 2018-01-11
CY1119595T1 (el) 2018-03-07
IL214258A0 (en) 2011-09-27
LT3254675T (lt) 2019-06-25
PT3254675T (pt) 2019-06-14
CA2752048C (en) 2014-11-25
ES2731601T3 (es) 2019-11-18
KR20110118721A (ko) 2011-10-31
SMT201900432T1 (it) 2019-09-09
CA2752048A1 (en) 2010-08-19
EP3254675A1 (en) 2017-12-13
US20120022156A1 (en) 2012-01-26
SG173601A1 (en) 2011-09-29
EP2395979A2 (en) 2011-12-21
WO2010093944A3 (en) 2011-08-11
US20140235711A1 (en) 2014-08-21
KR20140016441A (ko) 2014-02-07
MX2011008344A (es) 2011-09-29
ES2646816T3 (es) 2017-12-18
CN102387789A (zh) 2012-03-21
AU2010213594B2 (en) 2013-11-14
CO6361904A2 (es) 2012-01-20
NZ594488A (en) 2013-10-25
US8747901B2 (en) 2014-06-10
MY173715A (en) 2020-02-18
LT2395979T (lt) 2017-12-11
EA023652B1 (ru) 2016-06-30
DK3254675T3 (da) 2019-06-24
ZA201105630B (en) 2012-04-25
EA201190092A1 (ru) 2012-02-28
EP2395979B1 (en) 2017-08-23
HRP20191092T1 (hr) 2019-11-29
JP2012518008A (ja) 2012-08-09
JP5775464B2 (ja) 2015-09-09
HUE035013T2 (en) 2018-05-02
PL2395979T3 (pl) 2018-02-28
HK1220130A1 (zh) 2017-04-28
BRPI1008023B1 (pt) 2019-12-31
DK2395979T3 (da) 2017-11-27
PT2395979T (pt) 2017-11-16
PL3254675T3 (pl) 2019-09-30
US9155721B2 (en) 2015-10-13
AU2010213594A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
BRPI1008023A2 (pt) forma de dosagem sólida
BR112013014361A2 (pt) forma de dosagem
DK2427449T3 (da) Vinylindazolylforbindelser
BR112012006859A2 (pt) compostos
DK2414015T3 (da) Laryngoskopsystem
DK2411442T4 (da) Umættet polyesterresin
DE112010002949A5 (de) Kupplungstastpunkte
EP2469625A4 (en) OMNIBUS BAR
EP2445547A4 (en) CATHETERISM SYSTEM
EP2491340A4 (en) TELEMETRY PHOTOGRAPHIC APPARATUS
EP2509489A4 (en) SPRINKLER FOR EARLY HEEL REMOVAL
EP2440486A4 (en) CABLE RETRACTION SYSTEM
BRPI1005525A2 (pt) compostos de azaazuleno
DK2430035T3 (da) Uracylspipooxetannukleosider
BRPI1008827A2 (pt) deisobutenizador
DE112010002728A5 (de) Turboinhalator
DE112009005323A5 (de) Hebelarmprüfmaschine
EP2446176A4 (en) CYLINDER SEAL
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BR112012004964A2 (pt) girocóptero
BRPI1008070A2 (pt) tricianoboratos
BR112012031102A2 (pt) forma de dosagem oral sólida
DK2483126T3 (da) Skinnekøretøj
DE112010004865T8 (de) Lamellennassreibkupplung
BRPI0807882A2 (pt) Forma de dosagem

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: REATA PHARMACEUTICALS HOLDINGS, LLC (US)